Previous 10 | Next 10 |
YAVNE, Israel, June 14, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced its participation in the upcoming Healthcare Virtual Conference Part II, organized by M...
2023-05-31 19:14:51 ET Summary MediWound, a company developing medical solutions for skin and burn conditions, is set to begin US distribution of its burn solution NexoBrid in Q3 2023. With a cash pile of over $57 million, the company will be able to cover operating expenses and t...
2023-05-30 15:01:52 ET MediWound Ltd. ( NASDAQ: MDWD ), an Israel-based developer of enzymatic therapeutics for tissue repair, lost ~7% Tuesday after announcing its Q1 2023 financials that failed to meet Street forecasts. The company reported $3.8M in revenue for the qua...
2023-05-30 10:53:10 ET MediWound Ltd. (MDWD) Q1 2023 Earnings Conference Call May 30, 2023 08:30 AM ET Company Participants Monique Kosse - LifeSci Advisors, IR Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chief Financial Officer Barry Wolfenson - Ex...
2023-05-30 07:04:45 ET MediWound press release ( NASDAQ: MDWD ): Q1 GAAP EPS of -$0.44 misses by $0.26 . Revenue of $3.8M (-13.6% Y/Y) misses by $1.35M . For further details see: MediWound GAAP EPS of -$0.44 misses by $0.26, revenue of $3.8M misses by $1.35M
On track to initiate EscharEx ® Phase III study in fourth quarter 2023 NexoBrid ® U.S. launch expected in early third quarter 2023 Cash of over $57 million; Operating cash runway through profitability Conference call begins today at 8:30 a.m. ...
2023-05-26 13:59:29 ET MediWound ( NASDAQ: MDWD ) is scheduled to announce Q1 earnings results on Tuesday, May 30th, before market open. The consensus EPS Estimate is -$0.43 (-258.3% Y/Y) and the consensus Revenue Estimate is $5.15M (+17.0% Y/Y). Over the last 1 year, ...
YAVNE, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its financial results for the first quarter ended March 31, 2023 on Tuesday, May 30, 2023. ...
YAVNE, Israel, May 09, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of t...
Data to be highlighted in oral and poster presentations YAVNE, Israel, April 26, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic solutions for tissue repair, today announced the Company will present ...
News, Short Squeeze, Breakout and More Instantly...
Research Published in THE LANCET's eClinicalMedicine EscharEx ® Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation Tissue YAVNE, Israel, July 29, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in ne...
Funds to be used for clinical development of EscharEx ® to treat diabetic foot ulcers (DFUs) Award advances MediWound’s DFU program and its future revenues four years ahead of original schedule YAVNE, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd....
Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd PR Newswire GOTHENBURG, Sweden , July 15, 2024 /PRNewswire/ -- Mölnlycke Health Care, a world-leading MedTech company specialising i...